Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX with or without losartan after radical surgery for pancreatic cancer
ChiCTR2500095733Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of losartan, oxaliplatin, irinotecan, folinic acid and fluorouracil in pancreatic cancer (PC) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Disease-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
losartanoxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500095733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095733.